Copy to clipboard 
With the acquisition of INNOTERE, Heraeus Medical has expanded its existing business and added resorbable biomaterials for bone regeneration to its product portfolio. The newly-introduced brand by Heraeus Medical, named “heracure,” currently comprises two products: heracure one and heracure 3D.
These products are calcium phosphate-based biomaterials for bone substitution, which can be applied or filled into existing non-infected and non-load-bearing bone defects. The lead product, heracure one, is a paste prefilled in an application syringe and ready to use without any additional preparation steps. heracure 3D are small-sized shaped bodies of various designs, based on the heracure one paste and produced through a patented 3D printing process.
INNOTERE developed and manufactured the products. The integration of INNOTERE into Heraeus Medical began at the start of 2025 and has been completed consecutively in the last months. INNOTERE will continue to operate from its location in Radebeul.
“With INNOTERE, we have found an ideal platform to continue our growth trajectory, whose high-quality, innovative product portfolio meets the essential needs of today’s orthopedic patients and supports individualized therapy approaches,” explained Andrew Williamson, Co-President of Heraeus Medical. “By complementing our proven product portfolio — bone cements for arthroplasty surgery — with the new product segment of resorbable biomaterials, we underscore our commitment to developing pioneering products that enable excellent treatment outcomes and foster growth in key therapeutic areas.”
Source: Heraeus Medical
With the acquisition of INNOTERE, Heraeus Medical has expanded its existing business and added resorbable biomaterials for bone regeneration to its product portfolio. The newly-introduced brand by Heraeus Medical, named “heracure,” currently comprises two products: heracure one and heracure 3D.
These products are calcium phosphate-based...
With the acquisition of INNOTERE, Heraeus Medical has expanded its existing business and added resorbable biomaterials for bone regeneration to its product portfolio. The newly-introduced brand by Heraeus Medical, named “heracure,” currently comprises two products: heracure one and heracure 3D.
These products are calcium phosphate-based biomaterials for bone substitution, which can be applied or filled into existing non-infected and non-load-bearing bone defects. The lead product, heracure one, is a paste prefilled in an application syringe and ready to use without any additional preparation steps. heracure 3D are small-sized shaped bodies of various designs, based on the heracure one paste and produced through a patented 3D printing process.
INNOTERE developed and manufactured the products. The integration of INNOTERE into Heraeus Medical began at the start of 2025 and has been completed consecutively in the last months. INNOTERE will continue to operate from its location in Radebeul.
“With INNOTERE, we have found an ideal platform to continue our growth trajectory, whose high-quality, innovative product portfolio meets the essential needs of today’s orthopedic patients and supports individualized therapy approaches,” explained Andrew Williamson, Co-President of Heraeus Medical. “By complementing our proven product portfolio — bone cements for arthroplasty surgery — with the new product segment of resorbable biomaterials, we underscore our commitment to developing pioneering products that enable excellent treatment outcomes and foster growth in key therapeutic areas.”
Source: Heraeus Medical
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
